Eva Kriegová, Doc., Ing

Institute of Immunology Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Czech Republic

Poster(s):

• 1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025